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Purpose: TGFβ induces the transformation of corneal keratocytes into fibroblasts and myofibroblasts 
resulting in the formation of corneal haze (scar) following injury. We investigated whether epigenetic 
modifications can prevent development of corneal haze in vivo using a rabbit model. 
Methods: In vivo studies with New zealand white rabbits were performed with –9.0 diopter 
photorefractive keratectomy (PRK) surgery using an excimer laser. Human stromal fibroblasts 
(HSF) were used for in vitro studies. HSF cultures at 70% confluence were exposed to TGFβ 
(1ng/ml) with or without SAHA (vorinostat) under serum-free conditions for five minutes. 
SAHA (25.0nM=0.06%) was applied topically on the rabbit cornea immediately after PRK. 
Cornea tissue was harvested at four weeks post-operatively and studied with Trypan blue 
exclusion, slit lamp biomicroscopy, TUNEL assay, real-time PCR, immunocytochemistry, 
immunocytochemistry, and western blotting techniques.
Results: Treatment with the FDA approved histone deacetylase inhibitor SAHA (0.06%) 
significantly reduced cellular markers of myofibroblast transformation and haze development 
(αSMA, fibronectin and phalloidin) in the rabbit cornea in vivo (up to 73%; p<0.001) and in 
HSF in vitro (46-83%; p<0.001). Furthermore, this dose appeared to be well tolerated and did 
not cause redness, swelling, or inflammation in the rabbit eye in vivo or alter HSF viability or 
phenotype in vitro. Other tested doses showed low efficacy or high toxicity.
Conclusions: This study suggests that epigenetic modification is a novel approach for treating 
corneal haze in vivo. Additionally, vorinostat (0.06%) is highly efficacious in reducing PRK-
induced corneal haze with minimal side effects in rabbit eyes in vivo. 
